Beta Bionics, Inc. plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026. The results will cover net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan channel. The Company’s management team will host in-person meetings in San Francisco from January 12-14, 2026 to discuss the results. Beta Bionics is a medical device company focused on improving the health and quality of life of insulin-requiring people with diabetes through innovative solutions like the iLet Bionic Pancreas. To learn more, visit their website.

Read more at “GlobeNewswire”: Beta Bionics to Pre-Announce Topline Fourth Quarter 2025